Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now